So-Yeon Kang
Biographic Data
| ID | 6070647 |
|---|---|
| NAME | So-Yeon Kang |
| GIVEN NAMES | So-Yeon |
| FAMILY NAME | Kang |
| SIGNATURE | KANG S |
| AFFILIATIONS | So-Yeon Kang, Laura Karas, and Gerard F. Anderson are with the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. Ge Bai is with the Johns Hopkins Carey Business School. |
| VERIFIED | No |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 1 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2019 |
| LATEST PUBLICATION YEAR | 2023 |
| H-INDEX | 1 |
Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance
This cohort study demonstrated that the $2000 out-of-pocket cap included in the Inflation Reduction Act may substantially moderate the potential increase in spending faced by individuals who use ultra-expensive drugs when moving from commercial insurance to Part D coverage
Guarding Against Seven Common Threats to the Credible Estimation of Covid-19 Policy Effects
Pharmaceutical Industry Support of US Patient Advocacy Organizations
Objectives. To examine whether the share of pharmaceutical industry funds allocated to patient advocacy organizations (PAOs) is disproportionately large in the United States relative to other industrialized countries and to compare pharmaceutical companies’ disclosure practices across industrialized countries. Methods. We examined funding of PAOs among the 10 largest pharmaceutical companies in 2016. We compared funding allocated to organizations…
Pharmaceutical Industry Support of US Patient Advocacy Organizations
Objectives. To examine whether the share of pharmaceutical industry funds allocated to patient advocacy organizations (PAOs) is disproportionately large in the United States relative to other industrialized countries and to compare pharmaceutical companies’ disclosure practices across industrialized countries. Methods. We examined funding of PAOs among the 10 largest pharmaceutical companies in 2016. We compared funding allocated to organizations…
Pharmaceutical Industry Support of US Patient Advocacy Organizations
Objectives. To examine whether the share of pharmaceutical industry funds allocated to patient advocacy organizations (PAOs) is disproportionately large in the United States relative to other industrialized countries and to compare pharmaceutical companies’ disclosure practices across industrialized countries. Methods. We examined funding of PAOs among the 10 largest pharmaceutical companies in 2016. We compared funding allocated to organizations…
Guarding Against Seven Common Threats to the Credible Estimation of Covid-19 Policy Effects
Comparison of Out-of-Pocket Spending on Ultra-Expensive Drugs in Medicare Part D vs Commercial Insurance
This cohort study demonstrated that the $2000 out-of-pocket cap included in the Inflation Reduction Act may substantially moderate the potential increase in spending faced by individuals who use ultra-expensive drugs when moving from commercial insurance to Part D coverage
Business (2 works) · Environmental health (2 works) · Medicine (2 works) · Population (2 works) · Accounting (1 work) · Accounting (1 work) · Beneficiary (1 work) · Biomedical Ethics and Regulation (1 work) · Cohort (1 work) · Context (archaeology) (1 work)